Symptom burden and quality of life in patients with high-risk essential thrombocythaemia and polycythaemia vera receiving hydroxyurea or pegylated interferon alfa-2a: a post-hoc analysis of the MPN-RC 111 and 112 trials.

ABSTRACT:

SUBMITTER: Mazza GL 

PROVIDER: S-EPMC9098160 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature